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Abstract
Background: Viola odorata, widely distributed in Eastern and Western Himalaya region is extensively used in
treatment of various respiratory ailment, calculous affections and nervous disorders. It is a rich source of alkaloids,
terpenes, flavonoids, glycosides, tannins as well as viola-quercitin and salicyclic acid known as natural aspirin. The
present study was aimed to isolate bioactive compounds from the aerial parts of V. odorata.
Methods: The isolated compound from aerial parts of V. odorata was identified grounded on observed spectral
data including ultraviolet–visible (UV–vis), Fourier-transform infrared, gas chromatography-mass spectroscopy,
1H and 13C-nuclear magnetic resonance. The antibacterial efficacy of isolated compound was determined by
disc diffusion method against five bacterial strains namely, Haemophilus influenzae (MTCC 3826), Pseudomonas
aeruginosa (MTCC 2474), Staphylococcus aureus (MTCC 1144), Streptococcus pyogenes (MTCC 422) and Streptococcus
pneumoniae (MTCC 655) and Minimum inhibitory concentrations (MICs) by a serial dilution method by using 96
well microtiter plates.
Results: Based on spectral data analysis, one new structurally related ionone-like compound known as 3-(2′,4′,6′,6′-
tetramethylcyclohexa-1′,4′-dienyl)acrylic acid (1) has been isolated from aerial parts of V. odorata, with significant
bioactivity. The antibacterial efficacy of compound 1 ranged between 7.3 ± 0.28 to 9.3 ± 0.28 mm against selected
respiratory bacteria at 6 mg/disc concentration. The MICs were recorded at 32–128 μg/ml. Streptococcus pyogenes
was fairly resistant and Haemophilus influenzae more sensitive than others.
Conclusions: By this study, it can be concluded that compound 1 has significant bioactive properties against
tested microorganisms. It validates its use as a new potential source of natural drug for curing the respiratory
diseases caused by selected microorganisms.
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Background
Natural products from medicinal plants, either as pure
compounds or as standardized extracts, provide a limit-
less opportunities for novel drugs discovery due to out-
standing availability of chemical diversity. Viola odorata
Linn. (Violaceae), commonly known as Sweet Violet,
English Violet or Common Violet and Gulbanafsa in
Hindi, is a medicinal herb natively from Mediterranean
countries and Asia Minor. The genus Viola contains
about 500 species worldwide. Currently, numerous
species and varieties of violet is known and used for the
extraction of their natural occurring phytoconstituents.
V. odorata has excessive medicinal values. Its aerial
parts were reported as antibacterial, antioxidant, anti-
inflammatory [1–3], and in treatment of bronchitis,
tonsillitis, respiratory catarrh, cough, asthma, calcu-
lous affections and nervous disorders [4, 5]. Recent
studies have reported the presence of antibacterial
cyclic proteins known as cyclotides, the positively
charged bracelet cyclotide cycloviolacin O2 (cyO2) in
V. odorata. It has been found efficient with killing
properties against gram negative bacteria including
Pseudomonas aeruginosa, Salmonella enterica serovar
Typhimurium LT2 [6, 7].
The ionones, dihydroionones, ionols and epoxy
ionones are some few representative group of com-
pounds explored in violet flowers [8–10]. They are
responsible for well natural fragrance with pleasant
woody-floral, violet-ionone like scent characteristics
[11]. Ionones and their derivatives are a member of
terpene, the naturally occurring unsaturated hydro-
carbons whose carbon skeletons are composed of
isoprene C5 units. The isomers and its derivatives
differ due to presence of double bond at 1 or 2 pos-
ition, and shifting of methyl group in cyclohexane
ring. They occur mainly in plant containing beta-
carotene. Based on the close structurally related de-
rivatives of ionone, they could be expected to exhibit
similar biological activities.
In present study, qualitative chemical screening of aer-
ial parts of V. odorata has led to isolation of compound
1 named as 3-(2′,4′,6′,6′-tetramethylcyclohexa-1′,4′-die-




All the chemicals and solvents, silica gel for column
chromatography of mesh 60–120, silica gel-G for TLC,
and silica gel 60 F254 (0.25 mm layer thickness pre-
coated on aluminium back), and iodine resublimed were
commercial and purchased from Merck, Aldrich and
Fluka and were used as received. All the other solvents
and chemical used were of HPLC or analytical grade.
Plant material and isolation procedure
The aerial parts of V. odorata were collected in April,
2012 from Haridwar and authenticated at Botanical Sur-
vey of India, Dehradun (BSD No. 113405). Powdered
material (1.2 Kg) was extracted successively with petrol-
eum ether (PET), acetone (ACE) and methanol (MeOH)
by using Soxhlet apparatus. The yield of MeOH extract
was 1.22 % w/w (14.6 g). The MeOH extract was frac-
tionated by column chromatography (CC) on a silica gel
(600 × 30 mm, 60–120 mesh size), and sequentially
eluted with chloroform (CHCl3)/ACE with a gradual in-
crement of the CHCl3 content (v/v 100:0, 95:5, 90:10,
85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, 50:50,
each 1000 ml), resulting in 11 lots (A-K) with each
20 fractions (A1-A20). Fraction G6-G20 and H1-H15
showed similar TLC pattern and purified by prepara-
tive TLC (prep-TLC) and finally at CHCl3/MeOH/
H2O mixture (v/v, 75:17:8). A yellowish powdered
compound 1 (21 mg) was obtained.
Instruments
UV–vis absorption spectra was recorded in the wave-
length range 190–800 nm with Shimadzu UV-1800
series Pharmac-spec UV–vis spectrophotometer (Japan).
The signals were acquired four times and the mean
signals were taken as the best value of the UV spec-
tra. Before every measurement the blank spectrum
was also recorded, and automatically subtracted from
the sample spectrum by the instrument software. The
IR spectra were recorded in the wave number range
400–4000 cm−1 on Varian 3100 FT-IR spectropho-
tometer (Perkin Elmer Spectrum Version 10.03.05).
The GC-MS spectra were recorded on Varian Saturn
(mass spec model). 1H and 13C NMR spectra were re-
corded on JEOL AL 300 FT-NMR spectrometer.
Chemical shifts are given as δ value with reference to
tetramethylsilane (TMS) as the internal standard.
Spectroscopic data of compound 1
Yellow powdered compound; UV λmax (MeOH) nm:
246.00, 202.00, 222.50; IR (KBr) νmax: 3429.50, 2919.91,
2851.39, 1563.04, 1436.62, 1384.56, 1167.41, 1093.92,
880.64 cm−1; GC-MS: m/z 207 [M +H]+ calcd: for
C13H19O2 (207.281);
1H NMR (300 MHz, DMSO-d6): δ
7.613 (1H, d, J = 8.14 Hz, H-3), 6.532 (1H, d, J = 8.17 Hz,
H-2), 5.406 (1H, s, H-5′), 2.436 (2H, s, Ha-3′, Hb-3′),
1.558 (3H, s, Ha-9′, Hb-9′, Hc-9′), 1.164 (3H, s, Ha-10′,
Hb-10′, Hc-10′), 0.757 (6H, s, Ha-7′, Hb-7′, Hc-7′, Ha-
8′, Hb-8′, Hc-8′), 3.330 (m, DMSO-d6);
13C NMR
(75.45 MHz, DMSO-d6): δ 171.645 (C-1), 158.716 (C-
3), 154.310 (C-5′), 130.834 (C-1´), 122.652 (C-2),
113.833 (C-4´), 107.423 (C-2´), 34.477 (C-3′), 34.405
(C-6′), 31.269 (C-7′), 28.969 (C-8′), 21.722 (C-9′),
21.431 (C-10′), 39.529 (DMSO-d6).
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Antibacterial assay
Microorganisms used
The bacterial strains causing respiratory tract infections
namely, Haemophilus influenzae (MTCC 3826), Pseudo-
monas aeruginosa (MTCC 2474), Staphylococcus aureus
(MTCC 1144), Streptococcus pyogenes (MTCC 422) and
Streptococcus pneumoniae (MTCC 655) were procured
from Institute of Microbial Technology (IMTECH),
Chandigarh. Bacterial strains were maintained at 4 °C on
nutrient agar medium.
Antibacterial testing
The in vitro antibacterial activity was tested by disc dif-
fusion method [12]. This method depends upon the dif-
fusion of the tested material to such an extent that
growth of the added microorganism is prevented entirely
in a zone around the disc containing a solution of tested
material. Muller Hinton Agar (MHA) was used for anti-
bacterial screening. 6 mg/disc concentration of com-
pound was impregnated on the discs. These discs were
placed on the surface of the agar plates already inocu-
lated with selected bacterial organisms. An additional
control disc without any sample but impregnated with
an equivalent amount of solvent (DMSO) was used in
the assay. Efficacy of compound 1 against bacteria was
compared with a broad-spectrum antibiotic erythro-
mycin as positive control. Plates were incubated at 37 °C
for 24 h in BOD incubator. The antibacterial activity was
interpreted from size of diameter of zone of inhibition
measured in millimetre (mm).
Determination of Minimum Inhibitory Concentrations
(MICs)
The broth microdilution method employed for the
determination of minimum inhibitory concentrations
(MICs) of compound 1 as according to the recommen-
dations of the National Committee for Clinical Labora-
tory Standards (NCCLS) by a serial dilution method by
using 96 well microtiter plates. Bacterial strains were
cultured at 37 °C in MHA medium. After 18 h incuba-
tion, bacterial suspensions were prepared in Mueller
Hinton Broth (MHB) and their turbidity was standard-
ized to 0.5 McFarland. Optical density of test strains
were confirmed on spectrophotometer (Shimadzu UV-
1800 series Pharmac-spec UV–vis spectrophotometer,
Japan) at A600. The bacterial density was 5 × 10
5. By
using multipipettor, 100 μl of broth medium dispensed
into all wells of microtitre plate. Total 11 dilutions
(1024–1.0 μg/ml) of compound 1 were prepared by two-
fold serial dilution method and 100 μl of each concen-
tration was placed into each well and mixed properly.
Column 12 was used as negative control. 5 μl of bacter-
ial cultures were dispensed into wells in column 11 to 1.
The plates were incubated at 37 °C. After 18–22 h, the
plates were observed and bacterial cultures streaked on
culture plates to check their purity.
Results and discussion
Chemistry
Analysis of spectroscopic data revealed that com-
pound 1 is 3-(2′,4′,6′,6′-tetramethylcyclohexa-1′,4′-die-
nyl)acrylic acid (Fig. 1). Its molecular formula was
assigned to be C13H18O2 [Elemental composition: (in %)
C, 75.69; H, 8.80; O, 15.51] according to 1H NMR, 13C
NMR and a quasi-molecular ion molecular ion peak in
GC-MS in at m/z 207 ([M +H]+ calculated for C13H19O2,
207.281).
The UV–vis spectrum of compound 1 [see Additional
file 1] indicated the absorption maxima characteristic for
π→ π* transitions for CH = CH of aromatic ring
(246.00 nm). FT-IR spectrum of compound 1 [see
Additional file 2] revealed the absorption band of O–H
stretching (3429.50 cm−1), C-H stretching (2919.91,
2851.39 cm−1), C = O stretching (1563.04 cm−1), C-H de-
formation of alkenes (1436.62, 1384.56 cm−1), C-O
stretching of alcohol (1167.41 cm−1), O-H deformation
of alcohol (1093.92 cm−1), and out plane deformation of
CH in alkene (880.64 cm−1).
The mass spectrum for compound 1 obtained by GC-
MS [see Additional files 3 & 4] revealed its molecular
formula could be assigned as [M] = [C13H18O2] with a
Fig. 1 Chemical structure of compound 1 i.e. 3-(2′,4′,6′,6′-
tetramethylcyclohexa-1′,4′-dienyl)acrylic acid
Table 1 Zone of inhibition of compound 1 and reference drug
(erythromycin) against respiratory tract pathogens
S.
no.
Microorganisms Diameters of inhibition zone (mm) ± SEMa
Compound 1 DMSO Erythromycin
1. H. influenzae 9.3 ± 0.28 - 9.6 ± 0.23
2. P. aeruginosa 7.6 ± 0.28 - 11.0 ± 0.40
3. S. aureus 7.6 ± 0.57 - 11.3 ± 0.23
4. S. pneumoniae 8.0 ± 0.50 - 8.3 ± 0.23
5. S. pyogenes 7.3 ± 0.28 - 13.3 ± 0.47
azone of inhibition in millimeter (mm) in triplicate expressed as means and
standard error of means (SEM); Disc diameter: 5 mm; Compound 1 concentration
was 6 mg/disc
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quasi-molecular ion molecular ion peak at m/z 207 [M +
H]+ = [C13H19O2]. Loss of a neutral ethane molecule
from quasi-molecular ion generates first daughter ion
with m/z 177 which corresponds to [M +H – C2H6] =
[C11H13O2]; further fragmentation of first daughter ion
and elimination of a neutral C = O molecule generates a
stable ion which corresponds to base peak at m/z 149
[M +H – C2H6 - CO] = [C10H13O]. Successive fragmen-
tation and loss of CO2, C2H2 and two CH4 neutral mole-
cules from quasi-molecular ion leads to generate a
molecule with m/z 105 corresponding to [M+H – CO2 –
C2H2 – 2CH4] = [C8H10].
The 1H NMR spectrum of compound 1 [see Additional
file 5] exhibited that it contain two ethylenic protons
indicated by two doublets each for 1H at δH 7.613 (1H, d,
J = 8.14 Hz) and 6.532 (1H, d, J = 8.17 Hz), their spin
coupling pattern indicates presence of one cis-di-
substituted ethylene moiety in the molecule. It also repre-
sented two singlet one for a methine proton which appear
at δH 5.406 (1H, s) and one for two methylene protons at
δH 2.436 (2H, s). The compound also illustrated three
characteristic singlet for twelve methyl protons at δH
1.558 (3H, s), 1.164 (3H, s) and 0.757 (6H, s).
The 13C NMR spectrum of compound 1 [see
Additional file 6] marked the presence of thirteen signals
indicating the presence of thirteen carbon atoms in the
molecule. The highest downfield shift at δH 171.645 in-
dicates the presence of one carbonyl group (in form of
carboxylic acid). It represented six signals between δH
158.716 and 107.423 characteristic for six olefinic carbon
atoms. The spectrum also showed two signals each for a
secondary carbon at δH 34.477 and a quaternary carbon
at δH 34.405. The compound also demonstrated the
presence of four methyl carbon which signals at δH
31.269, 28.969, 21.722 and 21.431.
Antibacterial activity
The purified compound 1 was tested for antibacterial ac-
tivity against selected respiratory tract pathogens at
6 mg/ml concentration and showed better inhibitory ac-
tivities (Table 1). Compound 1 was found most efficient
against H. influenzae (9.3 ± 0.28 mm) and S. pneumoniae
(8.0 ± 0.50 mm) respectively. While erythromycin showed
inhibition ranged between 8.3 ± 0.23 to 13.3 ± 0.47 mm
which slightly higher values at similar concentration.
The MICs for compound 1 were ranged from 32 to
128 μg/ml (Fig. 2). The inhibition was observed similar
at 64 μg/ml against H. influenzae and S. aureus, 128 μg/
ml against P. aeruginosa and S. pneumoniae, and 32 μg/
ml against S. pyogenes.
Conclusions
In conclusion, present paper has shown the isolation and
structure elucidation of one new derivative of ionone like
compound named as 3-(2′,4′,6′,6′-tetramethylcyclohexa-
1′,4′-dienyl)acrylic acid (compound 1) from methanol
fraction of V. odorata with antibacterial activity. In regards
to antibacterial activity, compound 1 was significantly
active against tested respiratory tract pathogens including
H. influenzae, P. aeruginosa, S. aureus, S. pneumoniae and
S. pyogenes respectively.
Additional files
Additional file 1: UV–VIS spectrum of compound 1. (DOC 109 kb)
Additional file 2: IR spectrum of compound 1. (DOC 256 kb)
Additional file 3: GC-MS spectrum of compound 1. (DOC 134 kb)
Additional file 4: Mass spectrum of compound 1. (DOC 38 kb)
Additional file 5: 1H-NMR spectrum of compound 1. (DOC 97 kb)
Additional file 6: 13C-NMR spectrum of compound 1. (DOC 139 kb)
Fig. 2 Minimum inhibitory concentrations (MICs) of compound 1. The inhibition is noted at a) 64 μg/ml against H. influenzae and S. aureus, b)
128 μg/ml against P. aeruginosa and S. pneumoniae, and c) 32 μg/ml against S. pyogenes
Gautam et al. Clinical Phytoscience  (2016) 2:4 Page 4 of 5
Competing interests
Shiv Shanker Gautam, Navneet, Sanjay Kumar, Deepak Painuly and Jashbir
Singh declare that they have no competing interests.
Authors’ contributions
SSG participated on designing the study, carried out the research, collection
and analysing data and drafted the manuscript. N and SK participated in
planning and designing of study, supervised in laboratory data collection
and analysis. DP and JS participated in designing, data analysis and helped
to draft the manuscript. All authors read and approved the final manuscript.
Acknowledgments
Authors are grateful to the Head, Department of Botany & Microbiology,
Gurukul Kangri University, Haridwar for providing necessary facilities to
enable this research and Dr. Dmitry Kosyakov, Northern (Arctic) Federal
University, Arkhangelsk, Russia for help and suggestions in spectral analysis.
This investigation was supported by grant from UGC, New Delhi, India.
Author details
1Department of Botany and Microbiology, Gurukul Kangri University,
Haridwar 249404Uttarakhand, India. 2Department of Chemistry, Gurukul
Kangri University, Haridwar 249404Uttarakhand, India.
Received: 16 July 2015 Accepted: 23 January 2016
References
1. Arora DS, Kaur GT. Antibacterial activity of some medicinal plants. J Nat
Med. 2007;61:313–17.
2. Akhbari M, Batooli H, Kashi FJ. Composition of essential oil and biological
activity of extracts of Viola odorata L. from central Iran. Nat Prod Res.
2012;26(9):802–09.
3. Koochek MH, Pipelzadeh MH, Mardani H. The effectiveness of Viola odorata
in the prevention and treatment of formalin-induced lung damage in the
rat. J Herbs Spices Med Plants. 2003;10(2):95–103.
4. Vishal A, Parveen K, Pooja S, Kannappan N, Kumar S. Diuretic, laxative
and toxicity studies of Viola odorata aerial parts. Pharmacol Online.
2009;1:739–48.
5. Pullaiah T. Encyclopedia of world medicinal plants, vol. IV. New Delhi:
Regency Publications; 2006. p. 2048.
6. Ireland DC, Colgrave ML, Craik DJ. A noval suite of cyclotides from Viola
odorata: sequence variation and the implications for structure, function and
stability. Biochem J. 2006;400:1–12.
7. Pranting M, Loov C, Burman R, Goransson U, Andersson DI. The cyclotide
cycloviolacin O2 from Viola odorata has potent bactericidal activity against
gram-negative bacteria. J Antimicrob Chemother. 2010;65:1964–71.
8. Cu JQ, Perineau F, Gaset A. Volatile components of Violet leaves.
Phytochemistry. 1992;31(2):571–73.
9. Legnani L, Luparia M, Zanoni G, Toma L, Vidari G. A full conformational
characterization of natural ionones and irones, as well as 13-alkyl-
substituted α-ionones. Eur J Org Chem. 2008;28:4755–62.
10. Anca T, Philippe V, Ilioara O, Mircea T. Composition of essential oils of Viola
tricolor and V. arvensis from Romania. Chem Nat Comp. 2009;45(1):91–2.
11. Brenna E, Fuganti C, Serra S. Enantioselective perception of chiral odorants.
Tetrahedron Asymmetry. 2003;14:1–42.
12. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolke RH. Manual of clinical
microbiology. 4th ed. Washington: ASM; 1999. p. 1527.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Gautam et al. Clinical Phytoscience  (2016) 2:4 Page 5 of 5
